ALMS Company Profile and Key Details

ALMS has shown sold momentum, gaining 23.57% over the past week and 480.4% over the past quarter, though year-to-date performance is up 167.01%. Short-term trend indicators are bearishly aligned (SMA20 10.68%, SMA50 41.32%, SMA200 238.7%). The stock’s 14-day RSI is 69.08 (firm momentum), while the ATR of 1.84 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.03% below its high and over 986.19% above its low. Average 10-day trading volume of 1.21 million shares is below the 3-month average of 1.55 million, indicating normal recent market interest.

Alumis Inc. Common Stock (NASDAQ:ALMS) closed at $24.52 USD, losing -$0.47 (-1.90%) from the previous close of $24.99. The stock is currently mid-range between its 52-week high and low $2.76 and $30.60. With a market capitalization of about $3.02 billion, Alumis Inc. Common Stock is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.61). Key stats such as the average daily volume over the past year has been around 1.52 million shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Alumis Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Martin Babler, the company employs approximately 168 people and listed since February 22, 2021. Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

Alumis Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.53. This means the shares are trading above this model’s fair value.

Alumis Inc. Common Stock has 123.14 million shares outstanding. The public float is 91.18 million shares, elevated short interest at 12.86% of float. This equals 8.96 million shares. The short ratio is 6.89 days. Institutional investors hold 82.1% of the float. Insiders own 0.82%. Foresite Labs, LLC holds 2.91 million shares, Foresite Capital Management VI LLC has 2.91 million shares and Tananbaum James B. has 2.91 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Wall Street analysts project EPS growth of 35.7% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $55.00 to $14.00. The high target offers 120.09% upside. The low target suggests -43.98% downside. The mean target is $32.05. This offers 28.25% upside. Alumis Inc. Common Stock earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 13, 2025, missed forecasts by 15.22%. The prior quarter beat by 5.41%. Over the last six quarters, Apple has recorded several small beats. These include 1371.34% in August 13, 2024.

Alumis Inc. Common Stock (NASDAQ:ALMS) shares are up 167.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Alumis Inc. Common Stock trading at a premium to the broader market with a P/E of -10.75. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $28.45, suggesting 13.85% upside. Our AI forecast model points to short-term weakness (-4.28% over two weeks), a medium-term rise (37.98% over three months), and a longer-term gain (24.89% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Alumis Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.28%, with price expected at $23.92 by May 01, 2026, within a range of $22.75 to $25.12 3-Month Outlook: Projected rise of 37.98%, reaching $34.48 by July 16, 2026, with a range of $34.09 to $34.84. 1-Year Outlook: Projected gain of 24.89%, with price at $31.21 by April 16, 2027, within a range of $28.99 to $33.91.

Alumis Inc. Common Stock trades at a P/E ratio of -10.75, slightly below the S&P 500 average, with a price-to-sales ratio of 127.95 and a price-to-book ratio of 8.68 trading at moderately above to book value. The P/FCF stands at -8.31, also above market averages.